Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442260 · ClinicalTrials.gov registry record · Phase 1
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by West Virginia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00442260 is a Phase 1 study that has completed, run by West Virginia University. The registered enrollment target is 2 participants.
The verdict
NCT00442260, a Phase 1 study, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination with Abraxane (Abraxane) in Patients with Metastatic Breast Cancer (MBC) \[Phase I and II\]
Interventions
- DRUG Abraxane
- DRUG DOXIL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00442260
The ClinicalTrials.gov registry entry for NCT00442260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abraxane is the first listed.
NCT00442260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00442260 about?
NCT00442260 is a clinical study titled "Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer". Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination with Abraxane (Abraxane) in Patients with Metastatic Breast Cancer (MBC) \[Phase I and II\]
What is the current status of trial NCT00442260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2007-02. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00442260?
The interventions under investigation include: Abraxane (DRUG), DOXIL (DRUG).
Who is sponsoring clinical trial NCT00442260?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.